B细胞疗法在狼疮性肾炎中的应用概述
本文综述B细胞疗法在狼疮性肾炎中的现有经验。B细胞、浆母细胞和浆细胞是自身抗体来源,是狼疮性肾炎的潜在治疗靶点。然而随机临床试验结果未达预期,而无对照队列和观察性研究显示B细胞拮抗剂更有前景。文章分析可能限制其成功的因素,并提出基于B细胞管理的策略。
要点
- B细胞疗法在狼疮性肾炎随机临床试验中未达预期。
- 无对照队列和观察性研究显示B细胞拮抗剂更有前景。
- 需基于整体B细胞经验提出以B细胞为中心的管理策略。
核心结论
- B细胞疗法在狼疮性肾炎随机临床试验中未达预期,但观察性研究显示希望。
研究设计与样本
- 本文为综述,回顾B细胞疗法在狼疮性肾炎中的现有经验。
主要发现
- B细胞、浆母细胞和浆细胞作为自身抗体来源,在狼疮性肾炎发展中起主要作用。
- 随机临床试验未达预期,而无对照队列和观察性研究更有前景。
临床怎么用
- 基于B细胞经验,可考虑以B细胞为中心的方法管理狼疮性肾炎。
局限性
- 随机临床试验结果未达预期,可能限制B细胞疗法的成功。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is an autoimmune multisystem disease that commonly affects the kidneys. It is characterized by persistent autoantibody production that targets a multitude of self-antigens. B-cells, plasmablasts and plasma cells, as the source of these autoantibodies, play a major role in the development of lupus nephritis (LN), and are therefore promising therapeutic targets. To date, however, randomized clinical trials of B-cell therapies in LN have not lived up to expectations, whereas uncontrolled cohort and observational studies of B-cell antagonists have been more promising. In this article, we will review the current experience with B-cell therapy in LN and highlight the pitfalls that may have limited their success. We will conclude by suggesting B-cell-centric approaches to the management of LN based on what has been learned from the overall B-cell experience in SLE.
引用
- Almaani S, Rovin BH. B-cell therapy in lupus nephritis: an overview. Nephrol Dial Transplant. 2019. PMID: 30165690. doi:10.1093/ndt/gfy267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。